LMAT - ルメイトレ・バスキュラ― （LeMaitre Vascular Inc.） ルメイトレ・バスキュラ―LMATのチャート
LMATの企業情報
| symbol | LMAT |
|---|---|
| 会社名 | LeMaitre Vascular Inc （ルメイトレ・バスキュラ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ルメイトレ・バスキュラー(LeMaitre Vascular Inc.)は末梢血管疾患の治療用の医療機器を提供する。同社は主に血管手術の分野で使用される医療機器およびインプラントを開発、製造、販売する。同社は末梢血管疾患産業セグメントの治療用の医療機器およびインプラントの設計、マーケティング、販売および技術サポートに従事している。同社の製品ラインには、バルボロトーム、バルーンカテーテル、頚動脈シャント、生物学的血管パッチ、放射線不透過性マーキングテープ、吻合クリップ、遠隔内膜切除装置、腹腔鏡胆嚢摘出装置、人工血管移植、生物学的血管移植および動脈摘出装置が含まれる。末梢血管装置のポートフォリオは、「Expandable LeMaitre Valvulotome」、「Pruitt F3 Carotid Shunt」、「VascuTape Radiopaque Tape」、「XenoSure biologic patch」など、心臓以外の動脈および静脈に使用されるブランド名の製品で構成される。 ルメイトレ・バスキュラ―は、米国の医療機器製造業者。おもに末梢血管疾患の治療、手術分野向けに医療装置やインプラントの開発、製造、販売を行う。弁膜切開刀、バル―ンカテ―テル、頸動脈バイパス、生物学的パッチ、放射線不透過性マ―キングテ―プ、吻合クリップ、遠隔膜切除装置、腹腔鏡下胆嚢摘出装置、血管移植片、電動静脈切除装置を提供する。 LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. |
| 本社所在地 | 63 Second Avenue Burlington MA 01803 USA |
| 代表者氏名 | George W. LeMaitre ジョージW・ルミターレ |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 781-221-2266 |
| 設立年月日 | 30621 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2006年 |
| 従業員数 | 423人 |
| url | www.lemaitre.com |
| nasdaq_url | https://www.nasdaq.com/symbol/lmat |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 25.66000 |
| 終値（lastsale） | 28.42 |
| 時価総額（marketcap） | 553109642.12 |
| 時価総額 | 時価総額（百万ドル） 545.90870 |
| 売上高 | 売上高（百万ドル） 103.33200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） ー |
| 当期純利益 | 当期純利益（百万ドル） 20.40200 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 September 2018 LeMaitre Vascular Inc revenues increased 3% to $77.2M. Net income before extraordinary items increased 28% to $16.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Sales and Marketing - decrease of 30% to $13.6M (expense) Other General and Administrative decrease of 25% to $7.7M (expense). |
LMATのテクニカル分析
LMATのニュース
LeMaitre: Remaining Constructive On Long-Term Valuations (NASDAQ:LMAT) 2023/03/03 09:44:07 Seeking Alpha
LeMaitre Vascular continues putting its balance sheet to effective use, investing in strategic areas to fund future growth. Find out why LMAT stock is a Buy.
LeMaitre Vascular, Inc. (LMAT) Q4 2022 Earnings Call Transcript 2023/02/26 17:43:02 Seeking Alpha
LeMaitre Vascular, Inc. (NASDAQ:NASDAQ:LMAT) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ETCompany ParticipantsJ.J.
LeMaitre Vascular, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:LMAT) 2023/02/26 17:42:29 Seeking Alpha
The following slide deck was published by LeMaitre Vascular, Inc.
LeMaitre Vascular reports mixed Q4 earnings; initiates Q1 and FY23 outlook 2023/02/23 22:10:06 Seeking Alpha
LeMaitre Vascular press release (LMAT): Q4 GAAP EPS of $0.25 misses by $0.01.Revenue of $41M (+3.8% Y/Y) in-line.Business Outlook: Q1 2023 Guidance: Sales of $42.6M - $45.0M vs
LeMaitre Q4 2022 Financial Results 2023/02/23 21:03:00 GlobeNewswire
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.
LeMaitre: Remaining Constructive On Long-Term Valuations (NASDAQ:LMAT) 2023/03/03 09:44:07 Seeking Alpha
LeMaitre Vascular continues putting its balance sheet to effective use, investing in strategic areas to fund future growth. Find out why LMAT stock is a Buy.
LeMaitre Vascular, Inc. (LMAT) Q4 2022 Earnings Call Transcript 2023/02/26 17:43:02 Seeking Alpha
LeMaitre Vascular, Inc. (NASDAQ:NASDAQ:LMAT) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ETCompany ParticipantsJ.J.
LeMaitre Vascular, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:LMAT) 2023/02/26 17:42:29 Seeking Alpha
The following slide deck was published by LeMaitre Vascular, Inc.
LeMaitre Vascular reports mixed Q4 earnings; initiates Q1 and FY23 outlook 2023/02/23 22:10:06 Seeking Alpha
LeMaitre Vascular press release (LMAT): Q4 GAAP EPS of $0.25 misses by $0.01.Revenue of $41M (+3.8% Y/Y) in-line.Business Outlook: Q1 2023 Guidance: Sales of $42.6M - $45.0M vs
LeMaitre Q4 2022 Financial Results 2023/02/23 21:03:00 GlobeNewswire
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.
LeMaitre Vascular Stock: 16% Return Objective (NASDAQ:LMAT) 2022/06/24 15:03:18 Seeking Alpha
LeMaitre has been beaten down lately however the pullback lends significant opportunity to add to a long-term compounder. Read more about LMAT stock here.
Vascular Grafts Global Market Report 2022 2022/05/26 12:33:00 GlobeNewswire
Major players in the vascular graft market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic Plc, Getinge, Terumo Medical Corporation, and Gore Medical. Major players in the vascular graft market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic Plc, Getinge, Terumo Medical Corporation, and Gore Medical.
LeMaitre to Present at Upcoming Investor Conferences 2022/05/16 20:58:00 GlobeNewswire
BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences.